GP 119 - GliaPharma
Alternative Names: GP-119 - GliaPharmaLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator GliaPharm
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Astrocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; De Vivo disease; Unspecified
Most Recent Events
- 15 Oct 2024 GP 119 - GliaPharma is available for licensing as of 15 Oct 2024. https://gliapharm.com/partners/
- 14 Dec 2023 Preclinical trials in Alzheimer's disease in Switzerland (PO) (GliaPharma pipeline, October 2024)
- 14 Dec 2023 Preclinical trials in De Vivo disease in Switzerland (PO) (GliaPharma pipeline, October 2024)